BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 26797858)

  • 1. PAX2, PAX8 and CDX2 Expression in Metastatic Mucinous, Primary Ovarian Mucinous and Seromucinous Tumors and Review of the Literature.
    Ates Ozdemir D; Usubutun A
    Pathol Oncol Res; 2016 Jul; 22(3):593-9. PubMed ID: 26797858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PAX2 and PAX8 reliably distinguishes ovarian serous tumors from mucinous tumors.
    Wang M; Ma H; Pan Y; Xiao W; Li J; Yu J; He J
    Appl Immunohistochem Mol Morphol; 2015 Apr; 23(4):280-7. PubMed ID: 24992169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 4. PAX2, PAX8, and PR are correlated with ovarian seromucinous borderline tumor with endometriosis.
    Yun BS; Won S; Kim JH; Lee N; Kim M; Kim MK; Kim ML; Jung YW; Kim JY; Seong SJ; Shin E
    J Ovarian Res; 2022 Apr; 15(1):41. PubMed ID: 35387670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The utility of PAX8 and SATB2 immunohistochemical stains in distinguishing ovarian mucinous neoplasms from colonic and appendiceal mucinous neoplasm.
    Aldaoud N; Erashdi M; AlKhatib S; Abdo N; Al-Mohtaseb A; Graboski-Bauer A
    BMC Res Notes; 2019 Nov; 12(1):770. PubMed ID: 31771640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diffusely Metastasized Adenocarcinoma Arising in a Mucinous Carcinoid of the Ovary: A Case Report.
    Van Rompuy AS; Vanderstichele A; Vergote I; Moerman P
    Int J Gynecol Pathol; 2018 May; 37(3):290-295. PubMed ID: 28463910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical characterization of appendiceal mucinous neoplasms and the value of special AT-rich sequence-binding protein 2 in their distinction from primary ovarian mucinous tumours.
    Strickland S; Parra-Herran C
    Histopathology; 2016 Jun; 68(7):977-87. PubMed ID: 26542609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemistry in the Diagnosis of Mucinous Neoplasms Involving the Ovary: The Added Value of SATB2 and Biomarker Discovery Through Protein Expression Database Mining.
    Strickland S; Wasserman JK; Giassi A; Djordjevic B; Parra-Herran C
    Int J Gynecol Pathol; 2016 May; 35(3):191-208. PubMed ID: 26535987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PAX2 and PAX8 expression in primary and metastatic müllerian epithelial tumors: a comprehensive comparison.
    Ozcan A; Liles N; Coffey D; Shen SS; Truong LD
    Am J Surg Pathol; 2011 Dec; 35(12):1837-47. PubMed ID: 21989345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of REG4 in ovarian mucinous tumors.
    Huang Q; Chen X; Lu W; Lai M; Lu B
    Appl Immunohistochem Mol Morphol; 2014 Apr; 22(4):295-301. PubMed ID: 23958547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison of paired box genes 8 and 2 expression in epithelium tissues and the related tumors].
    Song Y; Huang X; Shen GH; Liu XY; Zhang X
    Zhonghua Zhong Liu Za Zhi; 2017 Jun; 39(6):424-428. PubMed ID: 28635231
    [No Abstract]   [Full Text] [Related]  

  • 12. Ovarian seromucinous carcinoma: report of a series of a newly categorized and uncommon neoplasm.
    Taylor J; McCluggage WG
    Am J Surg Pathol; 2015 Jul; 39(7):983-92. PubMed ID: 25723110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiating primary and extragenital metastatic mucinous ovarian tumours: an algorithm combining PAX8 with tumour size and laterality.
    Hu A; Li H; Zhang L; Ren C; Wang Y; Liu Y; Liu C
    J Clin Pathol; 2015 Jul; 68(7):522-8. PubMed ID: 25827135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian atypical proliferative (borderline) mucinous tumors: gastrointestinal and seromucinous (endocervical-like) types are immunophenotypically distinctive.
    Vang R; Gown AM; Barry TS; Wheeler DT; Ronnett BM
    Int J Gynecol Pathol; 2006 Jan; 25(1):83-9. PubMed ID: 16306790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of SATB2 in the differential diagnosis of intestinal-type mucinous tumors of the ovary: primary vs metastatic.
    Perez Montiel D; Arispe Angulo K; Cantú-de León D; Bornstein Quevedo L; Chanona Vilchis J; Herrera Montalvo L
    Ann Diagn Pathol; 2015 Aug; 19(4):249-52. PubMed ID: 26059401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of Cdx2 immunostaining in differentiating primary ovarian carcinomas from colonic carcinomas metastatic to the ovaries.
    Groisman GM; Meir A; Sabo E
    Int J Gynecol Pathol; 2004 Jan; 23(1):52-7. PubMed ID: 14668551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDX2 immunoreactivity in primary and metastatic ovarian mucinous tumours.
    Fraggetta F; Pelosi G; Cafici A; Scollo P; Nuciforo P; Viale G
    Virchows Arch; 2003 Dec; 443(6):782-6. PubMed ID: 14576939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7.
    Vang R; Gown AM; Wu LS; Barry TS; Wheeler DT; Yemelyanova A; Seidman JD; Ronnett BM
    Mod Pathol; 2006 Nov; 19(11):1421-8. PubMed ID: 16980943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases.
    Meagher NS; Wang L; Rambau PF; Intermaggio MP; Huntsman DG; Wilkens LR; El-Bahrawy MA; Ness RB; Odunsi K; Steed H; Herpel E; Anglesio MS; Zhang B; Lambie N; Swerdlow AJ; Lubiński J; Vierkant RA; Goode EL; Menon U; Toloczko-Grabarek A; Oszurek O; Bilic S; Talhouk A; García-Closas M; Wang Q; Tan A; Farrell R; Kennedy CJ; Jimenez-Linan M; Sundfeldt K; Etter JL; Menkiszak J; Goodman MT; Klonowski P; Leung Y; Winham SJ; Moysich KB; Behrens S; Kluz T; Edwards RP; Gronwald J; Modugno F; Hernandez BY; Chow C; Kelemen LE; Keeney GL; Carney ME; Natanzon Y; Robertson G; Sharma R; Gayther SA; Alsop J; Luk H; Karpinskyj C; Campbell I; Sinn P; Gentry-Maharaj A; Coulson P; Chang-Claude J; Shah M; Widschwendter M; Tang K; Schoemaker MJ; Koziak JM; Cook LS; Brenton JD; Daley F; Kristjansdottir B; Mateoiu C; Larson MC; Harnett PR; Jung A; deFazio A; Gorringe KL; Pharoah PDP; Minoo P; Stewart C; Bathe OF; Gui X; Cohen P; Ramus SJ; Köbel M
    Mod Pathol; 2019 Dec; 32(12):1834-1846. PubMed ID: 31239549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression of ARID1A in ovarian seromucinous neoplasms and its clinicopathological significance].
    Ding XH; Tian X; Wang LQ; Wang Y; Liu AJ
    Zhonghua Bing Li Xue Za Zhi; 2020 Jun; 49(6):588-593. PubMed ID: 32486536
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.